ELAN:NYE-Elanco Animal Health (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 11.14

Change

0.00 (0.00)%

Market Cap

USD 5.51B

Volume

3.18M

Analyst Target

USD 26.43
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-09 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 74.41B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 47.88B
HLN Haleon plc

N/A

USD 43.18B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 11.49B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 4.11B
BHC Bausch Health Companies Inc

N/A

USD 2.64B
CPHI China Pharma Holdings Inc

N/A

USD 3.69M
YCBD cbdMD Inc

N/A

USD 1.96M
APUS Apimeds Pharmaceuticals US, In..

N/A

N/A
EBS Emergent Biosolutions Inc

N/A

N/A

ETFs Containing ELAN

PETZ:LSE 11.16 % 0.00 %

N/A

N/A
KATZ:XETRA 9.20 % 0.00 %

N/A

N/A
PETZ:SW 9.20 % 0.00 %

N/A

N/A
DFE:SW WisdomTree Europe SmallCa.. 1.25 % 0.00 %

N/A

N/A
DFEA:SW WisdomTree Europe SmallCa.. 1.25 % 0.00 %

N/A

N/A
WTD7:F WisdomTree Issuer ICAV - .. 1.10 % 0.00 %

N/A

USD 0.06B
WTES:F WisdomTree Issuer ICAV - .. 1.10 % 0.00 %

N/A

USD 0.06B
DFE WisdomTree Europe SmallCa.. 0.00 % 0.58 %

N/A

N/A
IHE iShares U.S. Pharmaceutic.. 0.00 % 0.42 %

N/A

N/A
WTD7:XETRA WisdomTree Issuer ICAV - .. 0.00 % 0.00 %

N/A

N/A
WTES:XETRA WisdomTree Europe SmallCa.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.01% 36% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.01% 36% F 17% F
Trailing 12 Months  
Capital Gain -32.28% 21% F 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.28% 21% F 7% C-
Trailing 5 Years  
Capital Gain -54.72% 38% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.72% 38% F 6% D-
Average Annual (5 Year Horizon)  
Capital Gain -4.69% 36% F 13% F
Dividend Return -4.69% 29% F 9% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.38% 43% F 22% F
Risk Adjusted Return -10.80% 21% F 15% F
Market Capitalization 5.51B 56% F 79% B-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.